Cover Image
市場調查報告書

移植物抗宿主病(GVHD):全球臨床實驗趨勢

Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 180445
出版日期 內容資訊 英文 570 Pages
訂單完成後即時交付
價格
Back to Top
移植物抗宿主病(GVHD):全球臨床實驗趨勢 Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2017
出版日期: 2017年08月30日 內容資訊: 英文 570 Pages
簡介

本報告提供移植物抗宿主病(GVHD)相關之臨床研究最新趨勢分析,提供您疾病·治療方法概要,及G7及E7各國的臨床實驗狀況,各地區、各階段的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,並彙整有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 主要國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量: 免疫疾病治療藥臨床實驗的移植物抗宿主病 (GVHD)的比例

各期臨床實驗數量: G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量: 免疫疾病治療藥臨床實驗的移植物抗宿主病 (GVHD)的比例

各期臨床實驗數量: E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 移植物抗宿主病 (GVHD) 治療藥

有潛力的藥劑

最新臨床實驗新聞: 移植物抗宿主病 (GVHD)

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4524CTIDB

GlobalData's clinical trial report, "Graft Versus Host Disease (GVHD) Global Clinical Trials Review, H2, 2017" provides an overview of Graft Versus Host Disease (GVHD) clinical trials scenario. This report provides top line data relating to the clinical trials on Graft Versus Host Disease (GVHD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
  • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 26
  • Subjects Recruited Over a Period of Time 27
  • Clinical Trials by Sponsor Type 28
  • Prominent Sponsors 29
  • Top Companies Participating in Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials 31
  • Prominent Drugs 32
  • Latest Clinical Trials News on Graft Versus Host Disease (GVHD) 33
  • Aug 14, 2017: Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease 33
  • Jul 25, 2017: Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease 33
  • Jul 20, 2017: Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease 33
  • Jul 11, 2017: Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease 34
  • Jul 05, 2017: FDA Meeting Provides Clear Path for Cynata US Development Plans 34
  • Jun 26, 2017: Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy 35
  • Jun 24, 2017: European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids 35
  • Jun 23, 2017: Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease at R&D Day 35
  • Jun 14, 2017: Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model 36
  • Clinical Trial Profile Snapshots 37

Appendix 568

  • Abbreviations 568
  • Definitions 568
  • Research Methodology 569
  • Secondary Research 569
  • About GlobalData 570
  • Contact Us 570
  • Source 570

List of Tables

List of Tables

  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 16
  • Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, G7 Countries (%), 2017* 17
  • Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
  • Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, E7 Countries (%), 2017* 20
  • Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Phase, 2017* 23
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 24
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
  • Graft Versus Host Disease (GVHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures

List of Figures

  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 16
  • Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, G7 Countries (%), 2017* 17
  • Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
  • Graft Versus Host Disease (GVHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Graft Versus Host Disease (GVHD) to Immunology Clinical Trials, E7 Countries (%), 2017* 20
  • Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Graft Versus Host Disease (GVHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 23
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 24
  • Graft Versus Host Disease (GVHD) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
  • Graft Versus Host Disease (GVHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Graft Versus Host Disease (GVHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
  • GlobalData Methodology 569
Back to Top